Sevident
Leading an early-stage breast cancer detection startup
Concept
Sevident was a molecular sample prep company with a proprietary exosome capture technology. The technology has been applied across infectious diseases and oncology, with the first application in early-stage breast cancer identification. Sevident was a portfolio company of Incandescent, and I was appointed interim CEO to led a turnaround of the company.
No items found.
Team
Impact
I was the interim CEO of a team of 15 (scientists and consultants). Some highlights of my tenure include: securing a six figure convertible debt round and two key patents, closing negotiations for the company’s first international product partnership collaboration, and obtaining a contract with the National Cancer Institute.
Sevident successfully exited to an Australian publicly traded company, Sienna Cancer Diagnostics in April 2019. Sevident’s IP is currently being used as part of one of Australia’s leading life sciences companies as part of the diagnostic technology portfolio.
